PRME
Prime Medicine, Inc. NASDAQ Listed Oct 20, 2022$3.41
After hrs
$3.41
+0.00%
Mkt Cap $615.7M
52w Low $1.11
39.5% of range
52w High $6.94
50d MA $3.72
200d MA $4.06
P/E (TTM)
-2.5x
EV/EBITDA
-2.9x
P/B
4.2x
Debt/Equity
1.0x
ROE
-166.4%
P/FCF
-3.1x
RSI (14)
—
ATR (14)
—
Beta
2.67
50d MA
$3.72
200d MA
$4.06
Avg Volume
2.5M
About
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the ta…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | AMC | -0.25 | -0.22 | +12.0% | 4.23 | +1.2% | -2.6% | -7.1% | -5.2% | -2.8% | -4.3% | — |
| Nov 7, 2025 | AMC | -0.28 | -0.32 | -14.3% | 3.81 | +7.3% | -7.3% | +2.9% | -6.8% | -12.6% | -11.5% | — |
| Aug 7, 2025 | AMC | -0.36 | -0.41 | -13.9% | 3.68 | -0.3% | +3.0% | -4.6% | -6.0% | +3.5% | -1.1% | — |
| May 8, 2025 | AMC | -0.32 | -0.40 | -25.0% | 1.32 | +0.8% | -1.5% | +1.5% | -3.8% | -8.3% | -4.5% | — |
| Feb 28, 2025 | AMC | -0.37 | -0.31 | +16.2% | 2.52 | +2.8% | -11.1% | -12.3% | -8.3% | -8.7% | -4.8% | — |
| Nov 12, 2024 | AMC | -0.43 | -0.44 | -2.3% | 4.32 | -6.7% | -8.3% | -16.7% | -22.5% | -26.4% | -26.6% | — |
| Aug 8, 2024 | AMC | -0.40 | -0.46 | -15.0% | 4.39 | -1.4% | -4.3% | -5.9% | -2.3% | -6.4% | +0.0% | — |
| May 10, 2024 | AMC | -0.45 | -0.44 | +2.2% | 5.61 | +4.8% | +14.4% | +18.7% | +20.5% | +25.5% | +26.2% | — |
| Mar 1, 2024 | AMC | -0.48 | -0.56 | -16.7% | 8.74 | +1.9% | +0.3% | -7.7% | -3.7% | -6.9% | -7.6% | — |
| Nov 3, 2023 | AMC | -0.45 | -0.55 | -22.2% | 7.80 | +2.1% | -0.5% | +6.5% | -3.8% | -12.2% | -12.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 11 | Citigroup | Maintains | Neutral → Neutral | — | $3.53 | $3.50 | -0.8% | +11.0% | +0.6% | -5.7% | -4.5% | +8.2% |
| Nov 10 | Chardan Capital | Maintains | Buy → Buy | — | $3.81 | $4.09 | +7.3% | -7.3% | +2.9% | -6.8% | -12.6% | -11.5% |
| Aug 12 | Citigroup | Maintains | Neutral → Neutral | — | $3.51 | $3.60 | +2.6% | -1.4% | +8.5% | +3.7% | +1.7% | -0.3% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $3.68 | $3.67 | -0.3% | +3.0% | -4.6% | -6.0% | +3.5% | -1.1% |
| May 27 | Citigroup | Downgrade | Buy → Neutral | — | $1.29 | $1.26 | -2.3% | -1.6% | -1.6% | -2.3% | -8.5% | -7.8% |
| May 20 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.34 | $1.33 | -0.7% | -11.9% | -12.7% | -8.2% | -3.7% | -5.2% |
| May 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.34 | $1.33 | -0.7% | -11.9% | -12.7% | -8.2% | -3.7% | -5.2% |
| May 20 | JP Morgan | Downgrade | Overweight → Neutral | — | $1.34 | $1.33 | -0.7% | -11.9% | -12.7% | -8.2% | -3.7% | -5.2% |
| May 19 | Chardan Capital | Maintains | Buy → Buy | — | $1.59 | $1.39 | -12.6% | -15.7% | -25.8% | -26.4% | -22.6% | -18.9% |
| Mar 20 | Chardan Capital | Maintains | Buy → Buy | — | $2.00 | $2.06 | +3.0% | +0.5% | -2.5% | +1.5% | -2.5% | -2.5% |
Recent Filings
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
PRME's new CFO hire signals operational maturity and potential financial restructuring; investors should monitor whether improved financial controls and capital allocation justify the added executive compensation costs.
Apr 16
8-K · 7.01
! Medium
Prime Medicine, Inc. -- 8-K 7.01: Regulation FD Disclosure
Prime Medicine updated its corporate presentation on March 3, 2026, providing investors with current company information through their investor relations website.
Mar 3
Data updated apr 26, 2026 8:46pm
· Source: massive.com